Specifically, the findings of Kortse and colleagues that suggest PD1/PDL1 signaling is affected after anthracycline treatment, potentially contributing to an increased susceptibility to immune-related adverse events of subsequent anti-PD1/PDL1 cancer therapy requires further investigation [97]. The gene discussed is PDCD1; the disease is cancer.